Abstract
Background
Although overexpression of synuclein gamma (SNCG) has been reported in several cancers, few studies have been performed onSNCG in endometrial carcinomas.
Objective
This study aimed to investigate the role of SNCG in the progression of endometrial carcinoma.
Methods
The expression pattern and function ofSNCG gene were analyzed using the Gene Expression Omnibus (GEO) and Gene Set Enrichment Analysis (GSEA) datasets. Two vector types, containing either SNCG or negative control shRNAs, were used to evaluate cell proliferation, apoptosis, and metastasis using Cell Counting Kit 8, colony formation, flow cytometry, wound-healing, transwell, and invasion assays. The relative protein levels of N-cadherin, E-cadherin, vimentin, p-PI3K, PI3K, p-AKT, AKT, p-ERK, and ERK were determined by western bloting.
Results
Our results revealed thatSNCG mRNA expression and SNCG protein levels in shRNA-treated SPEC2 cells were lower than in the negative control cells. Furthermore, cell proliferation, migration, and invasion were significantly inhibited in SNCG shRNA-treated cells, but apoptosis was increased. The results of western blot analysis indicated that SNCG silencing reduced the protein levels of N-cadherin, vimentin, p-PI3K, p-AKT, and p-ERK, but not those of total PI3K, AKT, and ERK.
Conclusions
Therefore, shRNA-mediated suppression of SNCG inhibited SPEC2 cell proliferation, migration, and invasion, and promoted SPEC2 cell apoptosis, which was presumably accomplished via regulation of the PI3K/AKT/ERK signaling pathway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Change history
24 January 2024
A Correction to this paper has been published: https://doi.org/10.1007/s13258-023-01482-7
References
Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM (2007) Gamma-synuclein and the progression of cancer. FASEB J 21:3419–3430
Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464
Asati V, Mahapatra DK, Bharti SK (2016) PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem 109:314–341
Ball HG (1996) Do we know the best therapy for early endometrial cancer? Gynecol Oncol 60:173–175
Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88:2154–2163
Cirak Y, Furuncuoglu Y, Yapicier O, Alici S, Argon A (2015) Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer. Int J Clin Exp Pathol 8:5345–5353
Clayton DF, George JM (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21:249–254
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411
Gehren AS, Rocha MR, de Souza WF, Morgado-Diaz JA (2015) Alterations of the apical junctional complex and actin cytoskeleton and their role in colorectal cancer progression. Tissue Barriers 3:e1017688
Gerard C, Goldbeter A (2011) A skeleton model for the network of cyclin-dependent kinases driving the mammalian cell cycle. Interface Focus 1:24–35
Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, Xie Y, Zhang J, Chen Y, Budman DR et al (2007) Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer 121:1296–1305
He J, Xie N, Yang J, Guan H, Chen W, Wu H, Yuan Z, Wang K, Li G, Sun J et al (2014) siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK. J Breast Cancer 17:200–206
Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi YE (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57:759–764
Jia T, Liu YE, Liu J, Shi YE (1999) Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res 59:742–747
Kato T, Watari H, Endo D, Mitamura T, Odagiri T, Konno Y, Hosaka M, Kobayashi N, Todo Y, Sudo S et al (2012) New revised FIGO 2008 staging system for endometrial cancer produces better discrimination in survival compared with the 1988 staging system. J Surg Oncol 106:938–941
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG, Gynecologic Oncology G (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751
Lanciano RM, Greven KM (1995) Adjuvant treatment for endometrial cancer: who needs it? Gynecol Oncol 57:135–137
Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ (2004) Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer 101:58–65
Mhawech-Fauceglia P, Wang D, Syriac S, Godoy H, Dupont N, Liu S, Odunsi K (2012) Synuclein-gamma (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. Gynecol Oncol 124:148–152
Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ, Buttin BM (2009) Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 114:293–298
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T et al (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10:4125–4133
Orr JW Jr, Roland PY, Leichter D, Orr PF (2001) Endometrial cancer: is surgical staging necessary? Curr Opin Oncol 13:408–412
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047
Schaal K, Hirschfeld M, Bronsert P, Fullgraf H, Jager M, Herde B, Nothling C, Mayer S, Erbes T, Stickeler E (2015) Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform. Oncotarget 6:22553–22563
Shi H, Lu Z (2007) The Latest Progress in Studies of Mitotic Checkpoint Gene BubR1. Progress Modern Biomed 7:1110–1112 (1115)
Singh VK, Zhou Y, Marsh JA, Uversky VN, Forman-Kay JD, Liu J, Jia Z (2007) Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res 67:626–633
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
Surgucheva I, McMahan B, Ahmed F, Tomarev S, Wax MB, Surguchov A (2002) Synucleins in glaucoma: Implication of γ-synuclein in glaucomatous alterations in the optic nerve. J Neurosci Res 68:97–106
Surgucheva IG, Sivak JM, Fini ME, Palazzo RE, Surguchov AP (2003) Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. Arch Biochem Biophys 410:167–176
Surgucheva I, Newell KL, Burns J, Surguchov A (2014) New α- and γ-synuclein immunopathological lesions in human brain. Acta neuropathologica Commun 2:132–132
Surguchov A (2015) Chapter Four - Intracellular Dynamics of Synucleins: “Here, There and Everywhere”. In: Jeon KW (ed) International Review of Cell and Molecular Biology, vol 320. Academic Press, pp 103–169
Surguchov A (2016) Surguchov A. Gamma-Synuclein as a cancer biomarker: viewpoint and new approaches. Oncomedicine 1:1–3.https://doi.org/10.7150/oncm.16748
Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142
Yang YM, Yang WX (2017) Epithelial-to-mesenchymal transition in the development of endometriosis. Oncotarget 8:41679–41689
Ye Q, Feng B, Peng YF, Chen XH, Cai Q, Yu BQ, Li LH, Qiu MY, Liu BY, Zheng MH (2009) Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116. World J Gastroenterol 15:5035–5043
Zhou J, Tao D, Xu Q, Gao Z, Tang D (2015) Expression of E-cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol 8:3150–3154
Funding
None.
Author information
Authors and Affiliations
Contributions
MN and XW conceived and designed the experiments, MN and YZ analyzed and interpreted the results of the experiments, MN performed the experiments.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval
All animal experiments in this study were approved by the Institutional Animal Care and Use Committee of the Zhejiang Chinese Medical University.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ni, M., Zhao, Y. & Wang, X. Suppression of synuclein gamma inhibits the movability of endometrial carcinoma cells by PI3K/AKT/ERK signaling pathway. Genes Genom 43, 633–641 (2021). https://doi.org/10.1007/s13258-021-01080-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13258-021-01080-5